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Abstract 
Phosphoinositide (PIP) lipids regulate many aspects of cell function in the nervous system including 
receptor signalling, secretion, endocytosis, migration and survival. Levels of PIPs such as PI4P, 
PI(4,5)P2 and PI(3,4,5)P3 are normally tightly regulated by phosphoinositide kinases and 
phosphatases. Deregulation of these biochemical pathways leads to lipid imbalances, usually on 
intracellular endosomal membranes, and these changes have been linked to a number of major 
neurological diseases including Alzheimer’s, Parkinson’s, epilepsy, stroke, cancer and a range of rarer 
inherited disorders including brain overgrowth syndromes, Charcot-Marie-Tooth neuropathies and 
neurodevelopmental conditions such as Lowe’s syndrome. This article analyses recent progress in 
this area and explains how PIP lipids are involved, to varying degrees, in almost every class of 
neurological disease.  
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1.0 Introduction 
Phosphoinositides (PIPs) are structurally related and functionally diverse phospholipid molecules 
with many important roles in the nervous system. These functions include substrate supply to 
receptor-stimulated phospholipase C (PLC) and phosphoinositide 3-kinase (PI3K) signalling pathways, 
ion channel regulation, the control of intracellular vesicular trafficking, cytoskeletal organisation and 
protein-mediated inter-organelle lipid transport [1, 2]. Excluding the parent molecule 
phosphatidylinositol (PI) there are seven different lipids in the PIP family, consisting of PI4P, 
PI(4,5)P2, PI(3,4,5)P3, PI(3,4)P2, PI(3,5)P2, PI3P and PI5P. The different PIPs are formed by a collection 
of phosphoinositide kinase and phosphatases that catalyse the stepwise phosphorylation and 
dephosphorylation of hydroxyl groups on different positions of the inositol head group (Figure 1) [3]. 
In the nervous system, as in other mammalian tissues, the highest mass levels are for PI, followed by 
PI4P and PI(4,5)P2, with much lower and often transient agonist-stimulated peaks of the D3-
phosphorylated lipids formed through receptor-activated phosphoinositide 3-kinase pathways[3].  
1.1 Signalling by PI4P and PI(4,5)P2 
Levels of PI4P and PI(4,5)P2 undergo rapid depletion and resynthesis following agonist activation of 
heterotrimeric G protein-coupled receptors (GPCRs) that signal through PLC. PLC activation, usually 
initiated via Gq subunits, induces substantial PI(4,5)P2 hydrolysis and results in the formation of the 
second messengers inositol(1,4,5)-trisphosphate and diacylglycerol that mediate Ca2+ release from 
the endoplasmic reticulum and also PKC activation. GPCRs that signal through this route are high-
profile drug targets in the treatment of neurological diseases. Examples include Alzheimer’s disease 
where both orthosteric and allosteric ligands for the M1 muscarinic receptor [4] have been 
developed for the treatment of cognitive defects [5] and to inhibit the formation of neurofibrillary 
tangles and β-amyloid plaques [4, 6, 7]. Similarly, PLC-coupled delta opioid receptors are 
pharmacological candidates for chronic pain, epileptic seizures and locomotor disorders [8, 9]. While 
GPCR-specific ligands and individual receptor expression patterns in the CNS facilitate the targeting 
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of specific cell types and processes, drugs that inhibit PIP-metabolising enzymes also have some 
potential in the treatment of neurological diseases. Examples include the recent development of 
isoform-specific small molecule inhibitors of the PI(4,5)P2-metabolising enzymes PLC3 [10]and 
PIP5K1C [11] for the treatment of chronic pain. 
1.2 PI 4-kinases in the CNS 
Cellular PI4P levels are maintained by a family of four different PI 4-kinase (PI4K) enzymes: PI4K2A, 
PI4K2B, PI4KA and PI4KB (Figure 2). All four PI4K isozymes are expressed in the nervous system but 
they are targeted to different subcellular compartments including the trans-Golgi network (TGN), 
endosomes, secretory vesicles and the plasma membrane [12, 13]. More recent work investigating 
the pathways that supply PI4P to plasma membrane signalling processes has revealed that multiple 
PI4K isoforms at different cellular locations are required to maintain the signalling pools of PI4P and 
PI(4,5)P2 [14, 15]. PI4K2A, the crystal structure of which has been solved [16, 17], is by far the most 
abundant PI kinase activity measurable in brain membranes [18] and has been implicated in TGN-
endosomal sorting [19-24] and cell survival [18]. However, non-neuronal studies indicate that the 
wortmannin-sensitive PI4KA is likely to be the dominant isozyme for synthesizing the PI4P required 
for agonist-dependent signalling [25, 26].  
When considering the role of any PIP pathway in neurological disease it is important to note that 
each phosphoinositide-metabolising enzyme appears to possess a distinct protein interactome that 
operates in combination with catalytic activity to define its overall function in neuronal signalling 
and trafficking [13]. A well-studied example to illustrate these layers of complexity is PI4K2A, which 
synthesises a pool of PI4P on TGN and endosomal membranes, and which has also been visualised 
on secretory vesicles [22, 23, 27-32]. This enzyme contains an amino acid motif that can bind the E3 
ubiquitin ligase itch and this interaction facilitates reciprocal regulation of both enzymes’ catalytic 
activities [33]. This intermolecular association thereby functionally associates rates of endosomal 
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ubiquitination with membrane PI4P synthesis, and PI4P-dependent signalling and trafficking with 
protein targeting for degradation.  
In addition to effects on protein ubiquitination, the modular protein-binding functions of PI4K2A 
influence membrane sorting in TGN endosomal trafficking. PI4K2A contains a dileucine AP-3 clathrin 
adaptor-binding motif that partly mediates non-catalytic PI4K2A functions in cargo sorting and 
trafficking from the TGN to late endosomes [19]. Furthermore, PI4K2A has been shown in cross-
linking and proteomic studies to be a component of the multi-protein, biogenesis of lysosome-
related organelles complex-1 (BLOC-1) and also the Wiskott Aldrich Syndrome protein and scar 
homologue (WASH) complex that regulates the actin cytoskeleton [34]. In addition, PI4K2A has been 
shown to be a protein-binding partner for the R-SNARE protein VAMP3 [24]. Therefore, it is likely 
that alterations to PI4K2A expression can have ramifications for the numerous components of its 
associated protein interaction network and that these, in turn, can impact on the multiple neuronal 
roles that have been ascribed to this protein [20, 34-38]. There is also evidence for PI4K2A activation 
by the transcription factor c-FOS, which represents a novel avenue for research and potentially links 
alterations to PI4P synthesis with genomic transcriptional regulation [39, 40]. 
In conjunction with a repertoire of protein binding partners, post-translational modifications of 
PI4K2A are important for its intracellular trafficking functions. Recently, PI4K2A has been shown to 
be phosphorylated by GSK3 and this regulates PI4K2A-dependent trafficking of AMPA receptors by 
promoting the binding of the AP-3 clathrin adaptor [41]. The catalytic activity of PI4K2A is also 
regulated by post-translational modification. The rate of PI4P synthesis by PI4K2A is determined by 
non-covalent membrane interactions and the palmitoylation of two cysteine residues within the 
catalytic domain of the protein [42-45]. The membrane lipid environment and particularly the 
cholesterol content of these membranes can affect the enzyme’s catalytic activity [27, 46-48] and 
palmitoylation state, since the late Golgi-localised palmitoyl transferases that modify PI4K2A are also 
cholesterol sensitive [45]. Targeting of PI4K2A to cholesterol-rich membranes is also important for 
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its proposed role in regulating OSBP-dependent sphingomyelin synthesis at this subcellular location 
[49]. Hence, PI4K2A is an example of a single PI-utilising enzyme that integrates a membrane 
environment-sensitive catalytic function with a diverse range of non-catalytic functions that include 
protein targeting for degradation, endosomal trafficking and non-vesicular lipid transport, all of 
which are relevant to PIP disease pathways in the CNS. 
1.3 Generation of PI(4,5)P2 in the brain 
Resynthesis of PI(4,5)P2 requires PI4P 5-kinase activity by three main isozymes, PIPK1A, PIPK1B and 
PIPK1C (Figure 2). While evidence demonstrates that PIPK1A negatively regulates neurite outgrowth 
[50] and PIPK1B growth cone morphology [51], in the CNS at least, isoform-specific knockout studies 
in mice have revealed a dominant role for PIPK1C isozymes in PI(4,5)P2 generation [11, 52, 53]. 
PI(4,5)P2 can also be generated through the D4 phosphorylation of PI5P by PI5P 4-kinases [54]. PI5P 
can be synthesised by D5 phosphorylation of PI by PIKfyve (also known as Fab1) [55-57], but there is 
strong recent evidence that in cells PIKfyve phosphorylates PI3P to PI(3,5)P2, which is then 
dephosphorylated via 3-phosphatase activity to generate PI5P [58]. PI5P is a much less abundant 
lipid substrate than PI4P and hence, PI5P is a not the major source of cellular PI(4,5)P2 in the brain.  
1.4 PIP 5-kinase mutations in neurological diseases 
To date, there is only one direct example of a genetic mutation in either a PI4K or PIP 5-kinase 
causing a human disease and that is PIP5K1C in the rare autosomal recessive disorder lethal muscle 
contractural syndrome type 3 [59]. However, there has been an interesting development recently 
concerning the possible involvement of PIP5K1B in Friedreich’s ataxia [60], a multisystem disease 
that features pronounced neurodegeneration. The PIPK1B gene had previously been implicated as 
the cause of this disorder but subsequent papers revealed that this was probably a misidentification 
and concluded instead that Friedreich’s ataxia was due to silencing of the FTX gene which encodes 
the mitochondrial protein frataxin [61, 62]. However, Bayot and colleagues [60] have reported that 
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the GGA triplet repeat expansion that silences frataxin gene also results in cis-silencing of PIPK1B, 
leading to diminished PI(4,5)P2 production and striking disorganisation of the actin cytoskeleton [60]. 
These observations indicate that genetic impairment of PIPK1B function could contribute to some of 
the complicated clinical presentations of this ataxia.  
2.0 The channelopathies and disorders of PIP binding 
In addition to their roles in substrate supply to the PLC and PI3K signalling pathways [63], D4-
phosphorylated PIPs have important roles in ion channel regulation at the plasma membrane [15, 
64-79]. Lipids such as PI(4,5)P2 and PI4P can either positively or negatively [80] influence ion flux. 
This occurs through interactions with specific sites on channel proteins or through effects on 
membrane charge, and frequently in tandem with other modulators such as heterotrimeric G 
proteins subunits or subunit phosphorylation [73, 74, 81-83]. This lipid-based regulatory mode is 
relevant to neurological diseases since important pharmacological targets, for example, the KCNQ 
channel in epilepsy, are regulated by membrane PIP levels [76]. Furthermore, dysfunctional channel-
PIP interactions, usually due to genetic mutations affecting channel protein structure, lead to 
deregulated neuronal transmission. Diseases that feature this type of molecular mechanism are 
often collectively referred to as channelopathies.  
One well-established example of a channelopathy involving PIPs is a potassium-sensitive periodic 
paralysis with associated ventricular arrhythmias known as Andersen-Tawil syndrome [84-87]. This 
can be either an autosomal recessive disorder or occur sporadically and is caused by point mutations 
in PIP interaction sites on the KCNJ2 (Kir2.1) inwardly-rectifying potassium channel. Interestingly, 
while PI(4,5)P2 activates KCNJ2 opening the binding of other membrane PIP species inhibit this 
process by directly competing out PI(4,5)P2 binding [88]. Structural analysis of the protein family has 
revealed the presence of two distinct PIP interaction sites on the channel protein. The first PIP 
interaction site consists of a conserved non-specific phospholipid-binding region in the 
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transmembrane domain and a second site, located in the channel’s cytoplasmic tail, specifically 
binds PI(4,5)P2 [89]. Conversely, for potassium channels such the TRPV4 that are negatively 
regulated by PI(4,5)P2 binding, in this case via lipid biding to an ankyrin homology domain, mutations 
of the PIP interaction site result in augmented channel function [80], and this is relevant to TRPV4 
channelopathies such as Charcot-Marie-Tooth (CMT) type 2C and congenital distal and 
scapuloperoneal spinal muscular atrophy [80, 90-93].  
Another corollary of these recent insights is that the intramembrane balance of PI4P and PI(4,5)P2 is 
likely to be an important determinant of ion channel gating. Furthermore, distortions of this ratio, as 
can occur in inherited conditions characterised by PI(4,5)P2 phosphatase dysfunction, may be 
sufficient to cause ion channel deregulation [94, 95]. However, this is hitherto an underexplored 
area of neurological research. It is also important to mention that PIPs can influence ionotropic 
neurotransmission through vesicular trafficking processes that deliver, recycle and degrade plasma 
membrane-localised receptors, channels [13] and neurotransmitter transporter proteins [96]. These 
PIP-dependent processes have repercussions for receptor reserve and thus agonist efficacy, and 
collectively represent another route through which PIPs can modulate synaptic signalling. 
While much attention has focused on K+ channel regulation by PIPs, there is also a role for D3-
phosphorylated PIPs in this aspect of neurophysiology [97]. The best studied disease in this regard is 
mucolipidosis type IV, an autosomal recessive neurodegenerative disorder that can be caused by 
mutations in the PI(3,5)P2 interaction site on the TRPML1 channel, which localises to intracellular 
late endosomal/lysosomal membranes where it mediates metal cation efflux [98-100]. Significantly, 
a recent publication has described the development of small molecule activators of TRPML1 that can 
restore the function of PI(3,5)P2-insensitive structural variants that are also associated with the 
mucolipidosis phenotype [101]. This report sets an important precedent and indicates that 
molecules targeting PIP-channel interactions may be an important area for future drug development 
in neurodegenerative diseases. 
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2.1 Role of PIP protein binding domains in neurological diseases 
A recent proteomics study identified 405 PIP-interacting proteins, which unexpectedly means that 
this set of proteins is more numerous than the entire complement of proteins involved in either 
phosphoprotein or ubiquitin binding [102]. PIPs can influence a wide range of processes in neurons 
through the membrane recruitment of proteins containing either PI4P- or PI(4,5)P2-binding domains 
such as the PIP-specific pleckstrin homology (PH) domains, epsin N-terminal homology (ENTH) and 
AP180 N-terminal homology (ANTH) domains, and PX and FYVE domains [103]. These specific inter-
molecular interactions facilitate the spatial and temporal targeting of signalling proteins such as PLC 
and Akt during agonist-stimulated PIP signalling, and also the recruitment of membrane trafficking 
machinery such as epsin-1, AP-2, AP180 and dynamin to the plasma membrane for clathrin-
mediated coated pit formation and endocytosis. 
PI4P has an important role in targeting, via PH domain binding, lipid transfer proteins such as OSBP, 
CERT and FAAP2 to PI4P-enriched membranes at points of inter-organelle contact sites (reviewed in 
[13]). Furthermore, the recent finding that PI4P hydrolysis by Sac1 phosphatase releases energy to 
facilitate non-vesicular cholesterol transfer at Golgi-endoplasmic reticulum contact sites suggests an 
additional role for PIPs as a membrane-associated source of energy [104]. The implications of this 
unexpected finding for neurological diseases have yet to be explored but it is relevant to note that 
intracellular levels of lipids transported by PI4P-dependent processes, such as glucosylceramide, are 
frequently abnormal in diseases such as Parkinson’s and Gaucher’s [105].  
There are some instances in the literature of mutations in protein PH domains causing neurological 
and neuromuscular diseases. The best-studied example is the PI(4,5)P2-binding PH domain of 
dynamin 2, a GTPase required for the scission of clathrin-coated pits to form clathrin-coated vesicles 
during endocytosis and also the release of clathrin-coated transport vesicles during Golgi-to-
endosomal intracellular trafficking. A point mutation (K562E) in the dynamin 2 PH domain that 
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abolishes PI(4,5)P2 binding is associated with a dominant intermediate form of CMT neuropathy 
[106]. CMT disease describes a spectrum of progressive peripheral neuropathies with varying 
degrees of severity that can be caused by mutations in at least 60 genes affecting a number of 
biochemical pathways [107]. Mutations within the PH domain of this dynamin isoform have also 
been found in patients affected by other variations of CMT disease and also centronuclear myopathy 
[108-116]. However, it is important to note that not all disease-causing mutations within the 
dynamin PH domain also cause impaired PI(4,5)P2 binding [114]. Moreover, this type of disease 
association is not exclusive to dynamin isoforms and there are now several reports demonstrating 
that mutations in the PH domains of PLEKHG5 can also give rise to CMT symptoms [117, 118] and 
paediatric-onset lower motor neuron disease [119].  
3.0 CNS disorders caused by PI4P and PI(4,5)P2 imbalances 
There are examples of inherited but rare multisystem diseases caused by loss of function mutations 
in the PIP 5-phophatases and these have been extensively discussed in recent reviews of this area 
[120-123]. Of particular note in a neurological context is oculocerebrorenal syndrome of Lowe, 
sometimes referred to as Lowe’s syndrome or OCRL [124]. This is an X-linked recessive disorder and 
therefore only affects males. In addition to deleterious effects on the eyes and kidneys, OCRL 
presents clinically with neurological problems including intellectual impairment, developmental 
delays and behavioural problems. This disease is caused by loss of function mutations in the OCRL 
gene, which encodes a multidomain PIP 5-phosphatase that dephosporylates PI(4,5)P2 to produce 
PI4P [125-131]. OCRL has been localised to endosomes, the Golgi apparatus, the plasma membrane, 
phagosomes [132] and, importantly in terms of understanding current thinking on the disease 
mechanism, clathrin-coated vesicles [133]. Loss of OCRL activity leads to the build-up of PI(4,5)P2 on 
endosomal membranes and this feature of the disease drives actin accumulation and cytoskeletal 
abnormalities [134-138]. It is worth noting though that the case for PI(4,5)P2 accumulation 
underlying the neuropathological defects in OCRL is not proven. This is because Dent’s disease, 
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which is also caused by OCRL dysfunction, does not feature CNS involvement [136, 139, 140]. From 
this point of view, it is useful to consider how the non-catalytic functions of the OCRL protein might 
contribute toward the disease symptoms. Of particular interest in this regard is the PH domain of 
OCRL which does not bind PIPs but which instead contains a clathrin-interacting motif, and it is this 
motif that targets OCRL to late-stage clathrin-coated pits during endocytosis [137, 141]. OCRL1a, a 
splice variant only expressed in the brain, has a higher affinity for clathrin than the more 
ubiquitously expressed OCRL1b variant, and thus it may be specifically the loss of this protein-
interaction function that causes the neurological defects associated specifically with OCRL as 
opposed to Dent’s disease [142]. Reports that non-catalytic mutations in the APPL1-binding domain 
of OCRL are pathological [143] further support the idea that the phenotype of Lowe’s disease may 
be an aggregate manifestation of deficiencies in the OCRL1 protein interactome in tandem with 
abrogated PI(4,5)P2 homeostasis [144]. 
When considering the role of OCRL in degrading PI(4,5)P2, it is important to remember that there are 
other neuronal PIP phosphatases such as PIPP (INPP5J) and SHIP2, which can catalyse the D5 
dephosphorylation of both PI(4,5)P2 and PI(3,4,5)P3 but have nevertheless not yet been implicated in 
any OCRL-like pathology [120]. Furthermore, mutations of the PIP D5 phosphatases synaptojanin 
proteins (SYNJ1 and SYNJ2), which have roles in decoating clathrin-coated vesicles, do not feature in 
either Lowe’s or Dent’s disease. Hence although speculative, and notwithstanding some differences 
in PIP substrate preferences, these observations suggest very specific and non-overlapping roles for 
the D5 phosphatases in neuronal physiology and that dysfunction of these enzymatic pathways in 
neuronal disease cannot be explained simply by abrogated PI(4,5)P2 degradation. Instead, 
alterations to the non-catalytic functions of these enzymes, and also perhaps the highly localised 
changes to the minor endosomal pools of PI(4,5)P2 in the membrane domains where these proteins 
are specifically and temporally targeted, may hold the key to understanding how loss of function in 
PIP degradation leads to particular patterns of neurodegenerative disease.  
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4.0 Defective PI 3-kinase signalling in neurological disease – overgrowth and myelination disorders 
Phosphorylation of PI(4,5)P2 on the D3 position by class I PI3K catalytic subunits (PIK3CA, PIK3CB, 
PIK3CD and PIK3CG) can generate PI(3,4,5)P3, a molecule with important roles in both pro-survival 
[145-147]  cell migration signaling [148]. Phosphorylation of either PI4P or PI by class II PI3Ks such as 
PIK3C2A produces respectively PI(3,4)P2, a PIP species recently implicated in clathrin-mediated 
endocytosis [149] and also PI3P, which functions in primary ciliogenesis [150]. Individual PI3K 
isoforms can have multiple roles in the CNS. As an example of this diversity in neuronal functions, 
PIK3CG (more commonly referred to as PI3K) is required to maintain blood-brain barrier integrity 
during ischaemic reperfusion [151], has a function in memory and behaviour through NMDA 
receptor-stimulated long-term potentiation [152] and is a drug target in neuroinflammatory diseases 
such as multiple sclerosis [153]. 
In the nervous system, PI3K activity can be stimulated either by receptor tyrosine kinases or GPCRS; 
examples include insulin receptors activating PIK3CA isoforms or metabotropic glutamate receptors 
signaling via PI3KCB (reviewed in [154]). These signalling events dynamically control diverse 
physiological functions in the nervous system including protein synthesis [155, 156], long-term 
depression [152, 157, 158] and neuronal morphogenesis [159]. In healthy cells, the duration of 
PI(3,4,5)P3 signalling is limited due to its rapid dephosphorylation by PIP phosphatases such as PTEN 
and SHIP2. Moreover, several neurological diseases arise from gain of function and amplified 
PI3K/Akt/mTOR signalling and this is principally due to deregulated and constitutive activation of 
PI3K isoforms or loss of PI(3,4,5)P3 phosphatase activity. 
These numerous PI3K functions in the CNS  depend on the activation and membrane recruitment of 
protein kinases such as PDK1 and Akt isoforms and a range of effector proteins with PI(3,4,5)P3- and 
PI(3,4)P2-binding domains such as ARNO [160], which has been implicated in functions such as 
dendritic development. Significantly, a number of recent publications have revealed a crucial role for 
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PI(3,4,5)P3-dependent processes [161] and the PI3K/Akt/PTEN/mTOR signalling axis in myelination 
[153, 162-175], which is a key process in maintaining neuronal transmission, survival and recovery 
from trauma.  
 
4.1 PI3K and Akt3 link brain overgrowth with epilepsy and autism. 
In terms of neurological disease, one of the most striking developments in this field has been the 
number of recent reports implicating activating mutations in enzymes such as PIK3CA and Akt3 in a 
variety of brain overgrowth syndromes such as megalencephaly.  These disorders  feature increased 
numbers of both neurons and glial cells [176-182] and recent discoveries in this area are challenging 
for ideas that PIK3CA activating mutations and/or PTEN deletion are sufficient to drive malignancy to 
such an extent that certain cancers could be considered  ‘addicted’ to PI3K signalling [183].  
Hemimegalencephaly is a rare disorder featuring overgrowth of only one cerebral hemisphere and 
severe epilepsy. This type of cortical dysplasia is characterised histologically by dysfunctional cellular 
proliferation, differentiation and mislocalisation of particular neuronal cell types including 
GABAergic neurons, which are often dysfunctional in epilepsy [184]. Recently, Lee and colleagues 
[176] discovered that surgically resected diseased tissue from patients suffering from this disease 
was subject to a number of somatic mutations expected to cause constitutive activation of PI3K 
signalling to mTOR. As these mutations were only found in diseased brain regions, the authors 
concluded that this syndrome could be classified as a genetic mosaic disease. The somatic activating 
mutations identified were in the PIK3CA, AKT3 and MTOR genes. Interestingly, unlike in cancer 
where the PIK3CA activating mutation H1047R predominates, in hemimegalencephaly the activating 
E545K mutation is more common. Other mutations include a substitution in the N-terminal PH 
domain of AKT3, which is known to result in increased activation of the enzyme [185]. The 
biochemical consequences of the mTOR C1483Y mutation are not yet known, but the authors found 
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that in least some of these cases there was activation of S6 phosphorylation indicating upregulation 
of Akt-mTOR signalling. Simultaneous with the report of PI3K/AKT involvement in 
hemimegalencephaly, Rivière and co-workers [180] reported a range of mutations in AKT3, the 
regulatory PI3K subunit PIK3R2, and again in the PIK3CA protein in a number of related 
megalencephalies . Several subsequent studies in this area have also found AKT3 gain of function 
mutations either by gene amplification [182] or the E17K activating point mutation [179], which 
taken together demonstrate a remarkable and common dependency for activated and brain-specific 
Akt3 signalling in a whole spectrum of cerebral overgrowth disorders. In terms of understanding how 
AKT3 drives these proliferative pathologies, there is strong evidence that that it is due to inhibited 
cyclin D2 turnover leading to cell cycle defects [186]. Of importance in this regard are the converse 
findings that akt3 homozygous knockout mice have reduced brain size [187, 188] and that 
microcephaly in human disease is associated with haploinsufficiency of the chromosome 1q-
localised AKT3 gene [189]. 
An alternative means to amplify PI(3,4,5)P3 signalling and pathological brain growth would be via a 
loss of function mutation in PTEN, and there are reports of both frameshift and point mutations in 
PTEN causing extreme megacephaly and severe epilepsy often associated with autism [190]. Other 
defects in this lipid pathway, caused by mutations in the D4 phosphatase INPP4A, which 
dephosphorylates PI(3,4)P2 to PI3P, have been shown to cause NMDA receptor-mediated excitotoxic 
cell death, epilepsy and microcephaly [191-194]. In addition to revealing a major role for the PI3K 
signalling pathway in regulating brain development and size, there is now accumulating evidence 
that defective PTEN functioning and consequently mTOR activation are important in epilepsy and 
autism [190, 195-204]. Thus, enzymes in this pathway are candidate drug targets for non-surgical 
treatment of these neurological disorders.  
4.2 Neurological involvement in PTEN germline mutations and benign tumour growth 
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Germline loss of function mutations in PTEN give rise to an array of clinical syndromes, all of which 
feature benign and disorganised tissue overgrowth manifesting as neoplasia (hamartoma). The 
tissues affected and the severity of the condition can be highly variable even between siblings [205], 
but when caused by a germline PTEN loss of function mutation this group of diseases, which include 
Bannayan-Riley-Ruvalcaba syndrome and Cowden syndrome, are collectively referred to as PTEN 
hamartoma tumour syndromes (PHTS) [206]. As with sporadic or somatic mutations in PTEN, 
macrocephaly together with a cognitive impairment and developmental delays are common findings 
in PHTS. More recent work has found that similar to some somatic cerebral overgrowth disorders, 
there are instances of PIK3CA and AKT mutations in some Cowden syndrome patients, indicating a 
potential for upregulated PI(3,4,5)P3-dependent oncogenic transformation within affected tissues 
[207]. In line with this, there is a much increased risk of developing breast, thyroid, kidney, 
endometrial and colon cancers with PHTS [206, 208]. Neurological tumours such as neuromas [209] 
have sometimes been found in PHTS patients but it is not yet known how this relates mechanistically 
to PTEN gene anomalies.  
4.3 Activated PI3K signalling: overgrowth versus glioma 
The set of recent findings suggesting that PI3K pathway activations can cause brain overgrowth 
disorders but not necessarily cancer suggests the need for a critical re-evaluation of the proposed 
link between PTEN and glioma. The evidence for PTEN involvement in malignant brain tumours has 
accumulated over many years and for many cancers, there is a wealth of evidence from multiple 
studies indicating that PTEN is a tumour suppressor [210-216]. Furthermore, the genetic evidence 
for PTEN involvement in glioma is striking, with over 60% of advanced gliomas [215, 217-220] 
exhibiting genetic rearrangements leading to loss of PTEN function and knockdown studies on 
cultured cells demonstrating that ablated PTEN expression causes increased astrocyte proliferation 
and hypertrophy [221-223]. Many of the physiological roles attributed to PTEN concern the 
processes that arrange and organise the developing nervous system which, in turn, may relate to the 
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function of the enzyme in cell motility and adhesion [224-229]. A detailed characterisation of 
neuronal function in mice in which PTEN expression was ablated in neurons post-natally revealed 
that the main deficits were in synaptic plasticity and transmission, particularly in long-term 
potentiation and long-term depression, which manifested phenotypically as memory impairment 
[230]. Hence, in addition to developmental roles in organising the developing CNS, PTEN has 
physiological roles in neuronal transmission, indicating that changes to the enzyme’s activity or 
expression can have multiple consequences that extend beyond cell proliferation.  
Another point to consider is that unlike in PTEN overgrowth syndromes where there is often a single 
gene defect in PTEN or AKT, cancers are driven and evolve through several mutations, and for 
gliomas there is often co-upregulation of EGFR expression, leading to sustained receptor-driven 
signalling of not only PI3K but also other pro-oncogenic signalling pathways [210, 213, 231-244]. A 
switch to PTEN-dependent signalling is often a feature of more advanced tumours, possibly due to 
chromosome 10 loss of heterozygosity or resistance selection due to drug-induced inhibition of 
other proliferative pathways [214, 233, 234, 245]. In this way, upregulation of non-PIP oncogenic 
signalling networks may work in concert with PTEN deletions to generate a malignant phenotype 
and this may explain the mixed success so far in clinical trials of molecules that target solely 
upstream components of the receptor-PI3K signalling axis [246-251]. While PTEN is very well studied 
in glioma, other enzymes that can amplify PI3K signalling such as constitutively activating PIK3CA 
mutations [147, 212, 252, 253] also feature in many patients with this disease and indeed other 
neurological cancers including anaplastic oligodendrogliomas, anaplastic astrocytomas and 
medulloblastomas [254, 255].  
5.0 PI(3,5)P2 and Charcot-Marie-Tooth neuropathies 
PI(3,5)P2 is a quantitatively rare PIP that is found on endosomal membranes where it functions in the 
control of membrane fusion and dynamics [256]. PI(3,5)P2 is formed via D5 phosphorylation of PI3P 
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catalysed by PIKfyve [58] and is then rapidly dephosphorylated back to PI3P by Sac3, a PI(3,5)P2 5-
phosphatase encoded by the FIG4 gene [55, 57, 257-264]. Alternatively, PI(3,5)P2 can potentially be 
dephosphorylated to PI5P by as many as six of the catalytically active members of the myotubularin-
related 3-phosphatase family i.e. MTM1 (mutated in X-linked recessive centronuclear myopathy) 
[265], MTMR2, MTMR3, MTMR4, MTMR6, MTMR7 and MTMR8 (reviewed in [266, 267]). Alterations 
to PI(3,5)P2 levels in mice via knockout of the PIKfyve activator ArPIKfyve/Vac14 or Sac3/FIG4 
phosphatase lead to substantial neurodegeneration, hypomyelination defects and abrogated 
intracellular trafficking [268-270]. There are now several examples of neurological diseases in 
humans, including most prominently particular presentations of CMT disease, which are caused by 
genetic mutations that affect PI(3,5)P2 homeostasis [271].  
In terms of alterations to PIP metabolism, loss of function mutations in enzymes that 
dephosphorylate PI(3,5)P2 are prominent in the CMT4 subgroup of the disease, which is 
characterised by the paediatric onset of progressive axonal degeneration and associated myelin 
defects. Amongst the PI(3,5)P2 phosphatases associated with CMT4 are MTMR2 (CMT4B2) and its 
structurally related but catalytically inactive protein binding partner MTMR13 [172, 267, 272-278]. 
Mutations in the PI(3,5)P2 5-phosphatase Sac3/FIG4 that generates PI3P have also been implicated in 
CMT disease (CMT4J) [279], as well as other inherited neuropathies such as Yunis-Varón syndrome 
and amyotrophic lateral sclerosis [280, 281], all of which strengthen the case for a crucial 
physiological role for PI(3,5)P2 in maintaining normal neuromuscular functions and in particular 
myelination. Since the low abundance PIPs PI(3,5)P2, PI5P and PI3P are found mainly on endosomal 
and lysosomal membranes, these diseases are manifestations of defective PIP trafficking functions 
on these intracellular organelles that constitute the intracellular degradative trafficking pathway 
[256, 269]. This has led to the suggestion that these pathological examples of intracellular PI(3,5)P2 
dyshomeostasis could be considered as a class of endosomal-lysosomal storage disorder [282].  
5.1 Cilliopathies (Joubert’s and MORM syndromes) and INPP5E 
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INPP5E is a PIP 5-phosphatase that is highly active against PI(4,5)P2, PI(3,5)P2 and PI(3,4,5)P3 [122, 
283]. INPP5E localises to primary cilia [284, 285], which are single, microtubule-dependent, long, 
thin, membranous projections that are immotile and emanate from the centriole [286]. Primary cilia 
have been noted on many cell types including neurons [286-289] and while their functions are still 
being elucidated, they have been shown to function as specialised Ca2+ signalling organelles [290, 
291] and are also an important site for Hedgehog signalling [292, 293]. Primary cilia from radial glia 
are important for the formation of the cerebral cortex during brain development [294] and 
processes such as dendritic arborisation [295] and neuronal migration [296]. Ciliary defects feature 
in a variety of neurodevelopmental disorders [297] and mutations in INPP5E have been implicated in 
Joubert’s and MORM ciliopathies.  
Joubert’s syndrome is a ciliopathy characterised by abnormal development of the cerebellum and 
brainstem, which are identifiable as a signature ‘molar tooth’ structure when imaged [298]. 
Joubert’s ciliopathy has been associated with mutations in at least nine different genes, amongst 
which are mutations in the PIP phosphatase domain of INPP5E [299, 300]. Mutations in ARL13B, a 
small GTPase that forms a molecular complex with INPP5E [284, 294, 296], have also been 
implicated in Joubert’s syndrome, as have mutations in PDE6D, a protein that binds the membrane-
targeting prenyl groups of INPP5E [284, 301]. The related ciliopathy MORM is also due to loss of 
INPP5E function, although in this autosomal recessive disorder the mutation results in a truncated 
protein that nevertheless retains PIP phosphatase activity [302] but is no longer correctly targeted to 
the ciliary axoneme. PI3K signalling is required for the development of primary cilia [150] and 
current evidence suggests that INPP5E functions in the stabilisation of primary cilia as opposed to 
cilliogenesis [299]. These recent findings reveal a key role for the INPP5E signalling interactome in 
maintaining ciliar functionality and this is somewhat reminiscent of the situation in OCRL (another 
PIP-dependent ciliopathy) where mutations affecting molecular interactions in addition to catalytic 
activity can cause disease. Hence, the loss of INPP5E function and resulting 5-phosphorylated PIP 
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homeostasis tend to cause developmental abnormalities that are deleterious for the developing 
nervous system.  
6.0 The emerging story of PIPs in Alzheimer’s disease  
There is now a wealth of evidence implicating PIPs as potential biomarkers and as drug targets in 
Alzheimer’s disease. One of the most high-profile developments in this area has been the discovery 
that PI is one of only 10 serum lipids that can accurately predict memory loss in up to 90% of cases, 2 
years before the onset of dementia symptoms [303]. However, it is not clear yet whether raised 
serum PI reflects any particular change in PIP metabolism and indeed, the authors concluded that 
alongside the other biomolecules identified in their lipidomic screen, raised serum PI probably 
reports increased cell membrane breakdown. However, there are a number of observations that 
make the case for PIP involvement in Alzheimer’s disease. These are: 
1. The enrichment of PIP-metabolising enzymes such as PTEN [304] and lipids such as PI(4,5)P2 
[305] in neurofibrillary tangles. 
 
2. Alterations to PIP abundance and metabolism in diseased brains [304, 306-315]. 
 
3. Alterations to the catalytic activity of PIP-metabolising enzymes such as synaptojanin [316] 
and PI4K2A [317, 318], by binding of amyloid A peptides and conversely, the 
stimulation of A processing enzymes such as the -secretase complex by PIPs with 
particular acyl chains [319]. These results point to the existence of reciprocal product-
feedback loops on endosomal membranes that facilitate the cross-regulation of enzymes 
involved in PIP synthesis and amyloid processing. To further support this hypothesis, there is 
published evidence of a close correlation between cellular PI(4,5)P2 and 42-residue Aβ levels 
[308].  
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4. Genetic polymorphisms or mutations in genes encoding for PIP-utilising or interacting 
proteins such as PICALM, INPP5D and SYNJ1 predispose to Alzheimer’s disease [320-329]. 
These genes encode for phosphatidylinositol binding clathrin assembly protein (PICALM) 
[320-323, 330-334], which contains an N-terminal ANTH domain that binds PI(4,5)P2 [335, 
336] and can simultaneously bind clathrin by means of a clathrin-binding motif; the PI(4,5)P2 
5-phosphatase synaptojanin 1 [326, 328, 337], which is required for clathrin-mediated 
endocytosis [338]; and INPP5D, more commonly known as SHIP1 [339], which like PTEN is a 
PIP 3-phosphatase that preferentially dephosphorylates PI(3,4,5)P3 to PI(4,5)P2. Most recent 
evidence indicates that alterations to PICALM functioning leads to defects in autophagy and, 
in turn, this leads to the accumulation of tau, a process important for the development of 
Alzheimer’s disease [333]. While in Down’s syndrome, trisomy 21 results in increased SYNJ1 
gene copy number. This genomic change causes increased expression of synaoptojanin-1 
leading to decreased membrane PI(4,5)P2 levels and consequently endosomal trafficking 
defects [326]. This PIP defect is associated with concomitant reductions in A trafficking and 
clearance and, in this way, may contribute to the development of early-onset Alzheimer’s 
disease, which is common in Down’s syndrome [328, 340]. 
 
5. PI4P production by the endosomally localised PI kinase PI4K2A is stimulated by ginsenoside, 
a naturally occurring molecule that promotes A clearance in the brain of a murine 
Alzheimer’s model [341]. This effect may relate to cholesterol modulation of PI4K2A activity 
and its palmitoylation-dependent targeting to raft-like intracellular domains [27, 43-45, 48]. 
This may be further evidence that upregulating intracellular PIP production could be an 
effective means of countering abrogated A clearance.  
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6. A recent study has found increased neuronal levels of the PI(3,4,5)P3-activated protein 
kinase PDK1 both in Alzheimer’s and prion disease brains. This results in increased 
internalisation, through the caveolar route, of tumour necrosis factor-α-converting enzyme 
(TACE) receptor and subsequently reduced TACE-mediated -secretase activity at the cell 
surface [342]. Consequently, there is decreased proteolysis of both amyloid precursor and 
prion proteins and this leads to their aberrant accumulation. There is also a report that PDK1 
is required for A-mediated cell death [343]. These recent publications provide further 
evidence that PIP regulation of membrane trafficking pathways exert large effects on 
neuronal A levels. Similarly, the expression VPS34 (PIK3C3), an endosomal PI3K that 
synthesises PI3P, is reduced in the brains of Alzheimer’s patients and this leads to enhanced 
processing and reduced sorting of amyloid precursor protein through a mechanism involving 
ubiquitin-mediated trafficking and the PI3P-binding endosomal sorting complexes required 
for transport (ESCRT) components Hrs and Tsg101 [344]. VPS34 is widely expressed in the 
brain and its targeted ablation results in pronounced neurodegeneration and synaptic loss 
[345]. These combined insights suggest that PIP control of amyloid protein processing is an 
important process to understand as defects in these pathways are likely to cumulatively lead 
to amyloid plaque formation in the brain. 
6.1 Synaptojanin: a PIP link between Alzheimer’s and Parkinson’s diseases and epilepsy?  
The involvement of synaptojanin in Alzheimer’s is worth further comment since mutations in SYNJ1 
have been identified in a rare familial version of Parkinson’s disease [346-348] and also in an 
inherited form of Parkinson’s associated with epilepsy [349]. A separate study also reported a 
synaptojanin mutation in an inherited form of epilepsy, suggesting that SYNJ1 mutations can have 
heterogeneous effects on neuronal function that are not necessarily limited to classical Alzheimer’s 
and Parkinson’s symptoms [350, 351]. However, whilst Alzheimer’s may represent a gain of function 
in synaptojanin due to trisomy 21, the mutations associated with Parkinson’s disease and epilepsy 
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are loss of function point mutations in the SAC1 catalytic domain that should have the opposite 
effect on membrane composition and induce PI(4,5)P2 accumulation. Interestingly, lipidomic analysis 
of lipid raft composition in both early stage and incidental Parkinson’s patients revealed an increase 
in phosphatidylinositol levels, which is further evidence that PIP metabolism may be altered in this 
condition [352, 353]. Hence, it is possible that both Parkinson’s and Alzheimer’s, although affecting 
different brain regions and with different symptoms, are to some extent pathological manifestations 
of reciprocal PIP imbalances within the CNS. Moreover, PI4K2A modulation by cholesterol and 
ginsenoside point to a possible underappreciated role for PI4P levels in this equation and indicate 
that an impaired of balance of PI4P and PI(4,5)P2 binding partners may contribute towards the 
development of these neurological pathologies.  
It is worth noting that genetic mutations in synaptojanin 2 have not been found to cause Parkinson’s 
or Alzheimer’s disease. In terms of primary structure, the 2 synaptojanin isoforms are most 
divergent in their C-termini, with synaptojanin 2 containing a proline-rich region that is absent in 
synaptojanin 1, even though both proteins are thought to function in clathrin-mediated endocytosis. 
The SYNJ2 gene has gained some interest due to its potential role in maintaining cognitive ability and 
mental health in old age [354, 355], and also because a catalytically inactivating point mutation in 
this gene in the Mozart mouse strain leads to deafness caused by hair cell loss [356]. Since both 
synaptojanin proteins have similar PIP substrate specificities it may be the case that, as with the 
OCRL phosphatases, alterations to the membrane protein interactome in addition to lipid 
phosphatase activity may be an understudied determinant of how mutations in the D5 phosphatases 
can give rise to such a heterogeneous range of neurological defects.  
It is important to point out that other branches of the PIP signalling pathway are likely to be 
important in Parkinson’s disease. Particularly relevant in this regard is the mitochondrial protein 
PINK1 (phosphatase and tensin [PTEN] homologue-induced putative kinase 1), which is a 
downstream phosphorylation substrate of Akt and has been found to be mutated in a particular 
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early-onset inherited form of this neurodegenerative disorder [357-360]. In concordance with this, 
there is evidence that D2 dopamine receptor signalling via PI3K is anti-apoptotic and thus potentially 
neuroprotective in Parkinson’s disease [361].  
7.0 PIPs in stroke, exocitotoxic cell death and cerebral ischaemia 
While PIPs have many roles in inherited neuropathies, overgrowth syndromes and 
neurodegenerative disorders, there are also demonstrations that these lipids are important for CNS 
cell survival following the ischaemic trauma caused by a cerebral haemorrhage (stroke). Excitotoxic 
cell death due to augmented glutamate stimulation of NMDA receptors and Ca2+ dyshomeostasis is a 
common consequence in this type of brain injury and PIPs, in particular PI(3,4,5)P3, have been 
implicated in this neuropathological process [362].  
PIP levels, which are contingent on lipid kinase activity, ATP production and thus mitochondrial 
function, are known to decrease following periods of cerebral ischaemia [363-366]. Furthermore, 
there are strong indications from murine genetic models that PI4P production is important for the 
survival of particular cell populations in the CNS [18, 367]. In a rat model for transient forebrain 
ischaemia, PI4KA expression was found to be heavily downregulated, specifically in CA1 pyramidal 
neurons, as was its upstream lipid product PI(4,5)P2 [367]. This change in PIP metabolism correlated 
with increased neuronal apoptosis and was found to be reversible in cultured cell lines by re-
expression of catalytically active PI4KA [367]. These results are consistent with the idea that PI4P 
synthesis has anti-apoptotic functions in the brain [18]. However, most of the evidence for PIP 
involvement in cerebral trauma concerns a neuroprotective function for pro-survival PI3K and Akt 
signalling pathways [151, 368-376]. However, there is one report that PI3K activity has the opposite 
effect and promotes neuronal oxidative stress through PI(3,4,5)P3-dependent neuronal NADPH 
oxidase activation [369]. Some of the most unexpected findings in this arena have emanated from 
studies focused on identifying serum biomarkers from stroke patients. In one such study, an 
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unbiased proteomic screen found that an increased serum level of the PI(3,4,5)P3 phosphatase SHIP-
1 accurately predicted acute ischaemic stroke [377], whilst another found that anti-PI antibodies 
were prevalent in a group of young stroke patients [378]. These findings are difficult to rationalise 
based on any known disease mechanism and require validation in a larger patient cohort. 
Nevertheless, when viewed together with the demonstration that raised serum PI is an accurate 
biomarker for Alzheimer’s disease [303], there appears to be an emerging trend for PIP pathway 
molecules, which are not normally secreted at high levels, to be elevated in the serum of patients 
with severe neurological diseases. However, further work is needed to clarify the mechanisms that 
underlie these phenomena and also to probe the general applicability of these findings to other CNS 
disorders. 
8.0 Conclusions 
PIPs are involved in more or less every type of neurological disease, from rare and often devastating 
genetic diseases to more common neurodegenerative conditions such as Alzheimer’s that are 
becoming more widespread as life expectancy increases (Table 1). There has been substantial 
progress, particularly in the last 5 years, in understanding how PIP pathways mediate a range of 
physiological functions in the CNS and how genetic mutations affecting these pathways can lead to 
neurological diseases. However, with the notable exceptions of glioma, multiple sclerosis and to 
some extent Alzheimer’s disease, there has been less progress in translating this new knowledge 
into possible new treatments. Some of these problems are simply down to the fact that this 
information is novel and it will take some time and financial investment in order to generate, for 
example, small molecule inhibitors that are both isoform specific and blood-brain barrier permeable. 
Another issue is the complexity of the neurobiology regulated by the PIP lipids and the presence of 
compensatory and redundant biochemical pathways that could potentially confer resistance to 
targeted therapies. Even if treatment strategies remain challenging, it is fair to conclude that 
biomolecules associated with these pathways may be useful biomarkers for predicting, diagnosing 
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and classifying neurological conditions and also for discovering molecular connections between 
diseases that could inform future treatment strategies.  
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Legends 
Table 1. 
List of neurological diseases summarising the proteins, enzymes and PIP species involved.  
Figure 1. 
Diagram illustrating PIP metabolic pathways in the CNS and the enzymes that have been implicated 
in neurological diseases. Note that lipid kinases appear in red and phosphatases in blue. 
Figure 2. 
The structures of PI, PI4P and PI(4,5)P2.  A schematic diagram illustrating the molecular structures of 
the most abundant brain PIPs. The molecular species shown here are of the 1-stearoyl, 2-
arachidonoyl varieties which are the common acyl chain additions found in PIPs from the CNS.  The 
hydrophobic acyl chains anchor the PIPs in the membrane while the hydrophilic inositol headgroup. 
is exposed to the cytosol. Note that the charge differences between the different PIPs arise from 
single phosphorylation and dephosphorylation events on the inositol head group moiety and that 
these changes are due to the catalytic activities of phosphoinositide kinase and phosphatase 
enzymes.  Imbalances in the ratio of PI4P:PI(4,5)P2 may be important in both Lowe’s & Dent’s 
syndromes, Alzheimer’s  & Parkinson’s diseases.  Several inherited conditions with neurological 
involvement including Andersen-Tawil syndrome and a dominant intermediate presentation of 
Charcot Marie Tooth neuropathy are caused by mutations that abolish protein binding to PI(4,5)P2.
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Table 1 
 
 
Disease     Protein    Lipid 
 
PI(4,5)P2 imbalances 
Chronic pain    PIPK5K1C   PI(4,5)P2 
     PLCB3    PI(4,5)P2 
Friedreich's ataxia   PIP5K1B    PI(4,5)P2 
Lethal muscle contractural  
syndrome type 3    PIPK5K1C   PI(4,5)P2 
Charcot-Marie-Tooth disease   Dynamin   PI(4,5)P2 
(intermediate form and CMT2B) 
OCRL Lowe’s disease   OCRL1    PI(4,5)P2 
Dent’s disease    OCRL1    PI(4,5)P2 
 
Channelopathies 
Epilepsy     KNVQ channel   PI(4,5)P2 
Andersen-Tawil syndrome   KCNJ2 channel   PI(4,5)P2 
Charcot-Marie-Tooth type 2C  TRPV4 channel   PI(4,5)P2 
Mucolipidosis type IV   TRPML1 channel   PI(3,5)P2 
 
Defective PI3K pathways 
Multiple sclerosis    PIK3G    PI(3,4,5)P3 
Hemimegalencephaly   PIK3CA    PI(3,4,5)P3 
AKT3    PI(3,4,5)P3 
Megalencephaly    PIK3R2    PI(3,4,5)P3 
PIK3CA    PI(3,4,5)P3 
PTEN    PI(3,4,5)P3  
AKT3    PI(3,4,5)P3 
Microcephaly    INPP4A    PI(3,4)P2 
PTEN hamartoma tumour  
syndromes (PHTS)   PTEN    PI(3,4,5)P3  
Brain cancers    PTEN    PI(3,4,5)P3 
     PIK3CA    PI(3,4,5)P3 
X-linked recessive 
 centronuclear myopathy   MTM1    PI(3,5)P2 
CMT4B2     MTMR2    PI(3,5)P2 
CMT4J     Sac3/FIG4   PI(3,5)P2 
 
 
Table
Table 1 
 
 
Yunis-Varón syndrome    Sac3/FIG4   PI(3,5)P2 
Amytropic lateral sclerosis   Sac3/FIG4   PI(3,5)P2 
Joubert’s ciliopathy   INPP5E    PI(3,5)P2 /PI(3,4,5)P3 
MORM ciliopathy    INPP5E    PI(3,5)P2 /PI(3,4,5)P3 
Autism spectrum    PTEN    PI(3,4,5)P3 
     PIK3CA    PI(3,4,5)P3 
     PIK3C2A    PI(3,4)P2 
     PIK3R2    PI(3,4,5)P3 
Alzheimer’s and Parkinson’s diseases 
Alzheimer’s disease   PICALM 
     PI4K2A    PI4P 
     Synaptojanin 1   PI(4,5)P2 
     PDK1    PI(3,4,5)P3 
     VPS34    PI3P 
Parkinson’s disease   Synaptojanin 2   PI(4,5)P2 
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